Find trials
Search tips

A Study Of Organoids For Hypoxia-Induced Dysfunction In Hypertrophic Cardiomyopathy

Overview

About this study

The purpose of this study is to develop an in vitro cardiac organoid model representative of hypertrophic cardiomyopathy from myectomy-derived myocardial tissue. Investigate the impact of hypoxia on HCM pathophysiology and identify mechanisms driving differential susceptibility to hypoxia. Examine genotype-phenotype associations in HCM and sleep apnea susceptibility.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age.

  • Diagnosis of HCM meeting criteria for surgical myectomy.

Exclusion Criteria:

  • Declining consent for clinical samples to be stored.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/22/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Virend Somers, M.D., Ph.D.

Open for enrollment

Contact information:

Joshua Bock Ph.D.

(507) 422-0768

Bock.Joshua@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20593058

Mayo Clinic Footer